Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction

Biomarkers

Volumn 16, Issue 4, 2011, Pages 372-377

  Wang, Xinyu ^a,b,c   Xu, Shunlin ^a,b,c   Liang, Ying ^a,b,c   Zhu, Dan ^a,b,c   Mi, Lin ^a,b,c   Wang, Guisong ^a,b,c   Gao, Wei ^a,b,c  

^a PEKING UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Acute myocardial infarction; catecholamine; catestatin; hemodynamics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATESTATIN; CREATINE KINASE MB; NORADRENALIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMODYNAMICS; HUMAN; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; CHROMOGRANIN A; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART RATE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUROSECRETORY SYSTEMS; NOREPINEPHRINE; OBSERVATION; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 79957456922     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.578260     Document Type: Article

References (30)

1. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC. (2008). The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149:4780-4793.
2. Bacaner M, Brietenbucher J, LaBree J. (2004). Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease? Am J Ther 11:366-411.
3. Biswas N, Curello E, O'Connor DT, Mahata SK. (2010). Chromogranin/ secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 342:353-361.
4. Biswas N, Rodriguez-Flores JL, Courel M, Gayen JR, Vaingankar SM, Mahata M, Torpey JW, Taupenot L, O'Connor DT, Mahata SK. (2009). Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology 150:3547-3557.
5. Biswas N, Vaingankar SM, Mahata M, Das M, Gayen JR, Taupenot L, Torpey JW, O'Connor DT, Mahata SK. (2008). Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 149:749-757. (Pubitemid 351159350)
6. Brar BK, Helgeland E, Mahata SK, Zhang K, O'Connor DT, Helle KB, Jonassen AK. (2010). Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept 165:63-70.
7. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. (2002). Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23:967-974. (Pubitemid 35203876)
8. Cryer PE. (1992). Pheochromocytoma. West J Med 156:399-407.
9. Dev NB, Gayen JR, O'Connor DT, Mahata SK. (2010). Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 151:2760-2768.
10. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T. (2006). Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 152:927.e1-927.e6.
11. Foy SG, Crozier IG, Richards AM, Nicholls MG, Turner JG, Frampton CM, Ikram H. (1995). Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Eur Heart J 16:770-778.
12. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O'Connor DT. (2010). Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 32:278-287.
13. Gayen JR, Gu Y, O'Connor DT, Mahata SK. (2009). Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology 150:5027-5035.
14. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K. (2009). Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30:25-32.
15. Karlsberg RP, Cryer PE, Roberts R. (1981). Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 102:24-29. (Pubitemid 11086984)
16. Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O'Connor DT, Hook VY. (2003). Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry 42:6938-6946. (Pubitemid 36706476)
17. Mahapatra NR, Mahata M, Hazra PP, McDonough PM, O'Connor DT, Mahata SK. (2004). A dynamic pool of calcium in catecholamine storage vesicles. Exploration in living cells by a novel vesicletargeted chromogranin A-aequorin chimeric photoprotein. J Biol Chem 279:51107-51121. (Pubitemid 40017853)
18. Mahapatra NR, Mahata M, Mahata SK, O'Connor DT. (2006). The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens 24:895-904. (Pubitemid 43670461)
19. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. (2005). Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942-1952. (Pubitemid 40979734)
20. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT. (2003). Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058-32067. (Pubitemid 37048394)
21. Mahata SK, Mahata M, Wakade AR, O'Connor DT. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525-1535.
22. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997). Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623-1633. (Pubitemid 27425790)
23. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. (2002). Early decline in the catecholamine releaseinhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335-1345. (Pubitemid 34925678)
24. Petersen CL, Nielsen JR, Petersen BL, Kjaer A. (2003). Catecholaminergic activation in acute myocardial infarction: time course and relation to left ventricular performance. Cardiology 100:23-28. (Pubitemid 37140415)
25. Pfeifer K, Boe SP, Rong Q, Ebert SN. (2004). Generating mouse models for studying the function and fate of intrinsic cardiac adrenergic cells. Ann N Y Acad Sci 1018:418-423. (Pubitemid 38951435)
26. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115:2271-2281. (Pubitemid 46685895)
27. Rouleau JL, Moyé LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F. (1991). Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 68:80D-86D.
28. Sigurdsson A, Held P, Swedberg K. (1993). Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126:1068-1076. (Pubitemid 23330405)
29. Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothornsrikul S, Toneff T, Caporale C, Jiang Q, Parmer RJ, Hook VY, O'Connor DT. (2000). Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem 275:22905-22915. (Pubitemid 30646177)
30. Waldenström AP, Hjalmarson AC, Thornell L. (1978). A possible role of noradrenaline in the development of myocardial infarction: an experimental study in the isolated rat heart. Am Heart J 95:43-51.